B+
Bull case
25%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
RNA
Atrium TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-10
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
The August earnings release and SEC exhibit provide strong primary-source confirmation of IND clearance, Corventis launch, the second BMS milestone, and upcoming development milestones [#SEC-8K-2026-08-13]. Deterministic evidence has improved materially to a positive prior, but coverage remains low, social context is absent, the available recent news item is not company-specific, and analyst revisions or post-release price-reaction attribution are unavailable. This is a cautiously positive but still event-driven monitoring setup.
RankAlpha Sentiment Codex - 2026-09-10
Open full AI memoEvidence flagged
small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-09-30eventSecond Bristol Myers Squibb milestoneMedium impact
Atrium reported a second $15 million milestone under its BMS cardiovascular collaboration, to be recognized in third-quarter 2026 financial statements [#SEC-8K-2026-08-13]. The cash and partnership validation are supportive, but the benefit is largely known.
2026-12-31eventCorventis first-patient enrollmentHigh impact
Atrium has initiated clinical-site activities and expects to enroll the first participant in its ATR 1072 Phase 1/2 Corventis trial by the end of 2026 [#SEC-8K-2026-08-13]. Execution would provide the first clinical validation point for its precision-cardiology platform.
2027-09-30catalystInitial ATR 1072 proof-of-concept dataHigh impact
Atrium expects initial Corventis proof-of-concept data in the second half of 2027 [#SEC-8K-2026-08-13]. This is the largest potential value inflection, but clinical efficacy remains unproven and the timeline is distant.
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-10 • Updated nightlySource: Internal modelMethodology